Company intelligence / Profile preview

Ninsun Biotech

Monthey, Valais, Switzerlands-ge.com ↗

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

Ninsun Biotech has developed a patented diagnostic platform that identifies and characterizes cancer stem cells from biopsies. Their kits are CE-marked for colorectal and lung cancers with breast kit validation ongoing. The approach enables earlier characterization of aggressive tumors to inform treatment decisions. The company is transitioning from technical development to commercial rollout in Europe.

Therapeutic areas: Oncology
Modalities: Diagnostic kits based on stem cell detectionProprietary platform for cancer stem cell analysis
Industry: Pathology

Partnerships

BioArk incubator supportThe Ark Foundation start-up programCollaboration with GGBa & Economic Promotion Valais

Beyond the preview

Go deeper on Ninsun Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ninsun Biotech.

Explore the full profile